Amgen And Horizon Therapeutics Resolve FTC Lawsuit, Clearing Path To Close Acquisition; Narrow Assurance, Formalized In The Consent Order With The FTC, Will Have No Impact On Amgen's Business
Portfolio Pulse from Benzinga Newsdesk
Amgen and Horizon Therapeutics have resolved their FTC lawsuit, clearing the path for their acquisition to close. The narrow assurance formalized in the consent order with the FTC will not impact Amgen's business.
September 01, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The resolution of the FTC lawsuit and the impending acquisition will not have any impact on Amgen's business.
The news directly mentions that the FTC lawsuit resolution and the acquisition will not impact Amgen's business. Therefore, it's expected that the stock price will remain stable in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
The resolution of the FTC lawsuit clears the path for Horizon Therapeutics' acquisition by Amgen.
The news directly mentions that the FTC lawsuit resolution clears the path for Horizon Therapeutics' acquisition by Amgen. This could potentially lead to a short-term increase in Horizon's stock price due to the positive implications of the acquisition.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100